Annual Compliance Secretarial Report for year ended March 2026
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GlaxoSmithKline Pharmaceuticals Limited has filed its Annual Secretarial Compliance Report for FY2026, certified by Practicing Company Secretary P. N. Parikh of Parikh & Associates. The report, dated May 26, 2026, covers compliance with SEBI regulations including LODR, Prohibition of Insider Trading, Takeover Regulations, and Depositories Regulations. The company achieved full compliance across all 14 checkpoints, with zero violations, penalties, or deviations reported during the review period. No actions were taken by SEBI or stock exchanges against the company, its promoters, directors, or subsidiaries. Secretarial standards, board evaluations, related party transactions, and disclosure requirements all met applicable regulations.
This clean compliance report is positive for shareholders as it confirms the company maintained full regulatory compliance throughout FY2026 without any SEBI observations or enforcement actions.